Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: Results of a pilot study

Diseases of the Esophagus

Volumn 26, Issue 5, 2013, Pages 503-509

  Zhai, Y ^a   Hui, Z ^a   Wang, J ^a   Zou, S ^a   Liang, J ^a   Wang, X ^a   Lv, J ^a   Chen, B ^a   Zhu, H ^a   Wang, L ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Erlotinib; Esophageal cancer; Molecular targeted therapy; Radiotherapy; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; FEMALE; FOLLOW UP; HICCUP; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; LEUKEMIA; LIVER FUNCTION; LIVER INJURY; LUNG TOXICITY; MALE; NAUSEA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; RASH; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ERLOTINIB; ESOPHAGEAL CANCER; MOLECULAR TARGETED THERAPY; RADIOTHERAPY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; EXANTHEMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIATION PNEUMONITIS; RADIOTHERAPY, INTENSITY-MODULATED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84880332581     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2012.01380.x     Document Type: Article

References (21)

1. Orringer M B, Marshall B, Iannettoni M D. Transhiatalesophagectomy: clinical experience and refinements. Ann Surg 1999; 230: 392-400.
2. Wong R, Mahhaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; (25): 2092.
3. Van den Eynde M, Baurain J F, Mazzeo F etal. Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg 2011; 66: 10-7.
4. Lordick F, Ebert M, Stein H J. Current treatment approach to locally advanced esophageal cancer: is resection mandatory? Future Oncol 2006; 2: 717-21.
5. Kawaguchi Y, Kono K, Mimura K etal. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007; 97: 494-501.
6. Hanawa M, Suzuki S, Dobashi Y etal. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-80.
7. Ilson D H, Kelsen D, Shah M etal. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2011; 117: 1409-14.
8. Sutter A P, Hopfner M, Huether A etal. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer 2006; 118: 1814-22.
9. Dobelbower M C, Russo S M, Raisch K P etal. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anticancer Drugs 2006; 17: 95-102.
10. Li G, Hu W, Wang J etal. Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 2010; 78: 1407-12.
11. Yano H, Shiozaki H, Kobayashi K etal. Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma. Cancer 1991; 67: 91-8.
12. Shepherd F A, Rodrigues Pereira J, Ciuleanu T etal. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
13. Ku G Y, Ilson D H. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010; 36: 235-48.
14. Shimizu K, Hihara J, Yoshida K etal. Clinical evaluation of low-dose cisplatin and 5-fluorouracil as adjuvant chemoradiotherapy for advanced squamous cell carcinoma of the esophagus. Hiroshima J Med Sci 2005; 54: 67-71.
15. Kumekawa Y, Kaneko K, Ito H etal. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2006; 41: 425-32.
16. Ishikura S, Nihei K, Ohtsu A etal. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003; 21: 2697-702.
17. Morota M, Gomi K, Kozuka T etal. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 2009; 75: 122-8.
18. Devaraju C J, Lokanatha D, Bapsy P P etal. Risk scoring for predicting mucositis in Indian patients with esophageal carcinoma receiving concurrent chemoradiotherapy. Gastrointest Cancer Res 2009; 3: 4-6.
19. Rodriguez C P, Adelstein D J, Rice T W etal. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010; 5: 229-35.
20. Janmaat M L, Gallegos-Ruiz M I, Rodriguez J A etal. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-9.
21. Tew W, Shah M, Schwartz G etal. Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Proc Gastrointest Am Soc Clin Oncol Symp 2005; 85: 5a.